Antiplatelet agents and anticoagulants are a mainstay for the prevention and treatment of
thrombosis. However, despite advances in antithrombotic therapy, a fundamental challenge …

In 2014, a joint consensus document dealing with the management of antithrombotic therapy
in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or …

Stroke prevention in patients with atrial fibrillation (AF) is one pillar of the management of
this common arrhythmia. Substantial advances in the epidemiology and associated …

Despite advances in anticoagulant therapy, thrombosis remains the leading cause of
morbidity and mortality worldwide. Heparin and vitamin K antagonists (VKAs), the first …

The non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which
inhibits thrombin, and apixaban, betrixaban, edoxaban, and rivaroxaban, which inhibit …

Although anticoagulants have been in use for more than 80 years, heparin and vitamin K
antagonists were the sole available options until recently. Although these agents …

A thrombus is a blood clot that forms in the lumen of an artery or vein, restricting blood flow
and causing clinical symptoms. Thrombosis is associated with many life‐threatening …

Ginkgo Biloba leaf extract has been widely used for the prevention and treatment of
thrombosis and cardiovascular disease in both eastern and western countries, but the …

Activation of the blood coagulation cascade leads to fibrin deposition and platelet activation
that are required for hemostasis. However, aberrant activation of coagulation can lead to …

Background In recent years, many important advances have been seen in anticoagulation
therapy. However, bleeding risk is still a major concern. Factor XI (FXI) inhibition has …